In pharmaceutical process development, the molecule recorded as 5-Thiazolecarboxamide, 2-Amino-N-(2-Chloro-6-Methylphenyl)-—Chemical Abstracts Service Registry Number 302964-13-6—operates as the core heterocyclic scaffold for the multi-targeted tyrosine kinase inhibitor dasatinib. The empirical formula is C11H10ClN3OS, yielding a molecular weight of 267.73 g·mol−1. Physically, the neat solid exhibits an off-white to pale yellow crystalline powder morphology with a differential scanning calorimetry onset melting endotherm typically recorded between 208 °C and 212 °C at a heating rate of 10 °C·min−1 under nitrogen purge. Its utility is not that of a formulated finished product but of a regulated intermediate supplied to manufacturing sites operating under ICH Q7 Good Manufacturing Practice; the sulphur- and nitrogen-containing thiazole ring combined with the sterically hindered 2-chloro-6-methylphenyl amide appendage delivers the exact ATP-competitive binding geometry required by the BCR‑ABL kinase domain. The intermediate is produced via carbodiimide-mediated coupling of 2‑aminothiazole‑5‑carboxylic acid with 2‑chloro‑6‑methylaniline in anhydrous dimethylformamide, followed by anti-solvent crystallization from acetonitrile–water mixtures. Routine quality control relies on reversed‑phase high‑performance liquid chromatography (HPLC) using a C18 column (250 mm × 4.6 mm, 5 µm) with a mobile phase composed of 0.1 % phosphoric acid in water and acetonitrile (40:60 v/v) at 1.0 mL·min−1 and UV detection at 254 nm. Retention time consistency within ±0.15 min across a campaign is treated as an identity confirmation alongside Fourier‑transform infrared spectroscopy (FTIR) matching to a validated reference spectrum.
Why Does the 2‑Chloro‑6‑Methylphenyl Substituent Dominate Dasatinib’s Pharmacophore?
The selectivity profile of dasatinib hinges on a precise spatial arrangement where the 2‑chloro‑6‑methylphenyl moiety occupies a deep hydrophobic pocket of the Abl kinase, a region that is sterically inaccessible to the N‑des‑chloro or ortho‑unsubstituted analogues. In structure–activity relationship studies spanning a panel of recombinant Abl mutants, the removal of the 2‑chloro substituent reduces cellular IC50 by a factor exceeding 80‑fold against unmutated BCR‑ABL, as measured in K562 phospho‑CRKL ELISA assays. The product therefore differs fundamentally from other 2‑amino‑N‑arylthiazole‑5‑carboxamides offered as bulk intermediates for kinase inhibitor libraries; compounds carrying a 4‑methyl‑3‑nitrophenyl or 3‑(trifluoromethyl)phenyl group generate distinct hinge‑region interactions and cannot serve as direct precursors for dasatinib without extensive re‑engineering of the downstream synthetic route. Manufacturers who require a drop‑in replacement for the originally patented intermediate must verify by 1H‑NMR (DMSO‑d6) that the characteristic aromatic proton signals appear at δ 7.55 (d, J = 2.0 Hz, thiazole C4‑H) and δ 7.35–7.15 (multiplet, 3 aryl‑H) alongside a sharp singlet at δ 2.25 for the methyl group. This fingerprint discriminates the target compound from the regioisomeric 2‑chloro‑4‑methylphenyl amide and from des‑amino by‑products that accumulate when the coupling activation time is extended beyond 18 h at ambient temperature.
If Purity Falls Below 99.0 % as Determined by HPLC Area Normalization
Post‑recrystallization product routinely exceeds 99.5 % HPLC area purity when the crude cake is washed with chilled acetonitrile (0–5 °C) and dried in vacuo at 45 °C for 8 h. However, excursions below the 99.0 % threshold during scale‑up campaigns in 100‑L glass‑lined reactors have been traced to two failure modes. The first is residual 2‑chloro‑6‑methylaniline, a primary aromatic amine with a threshold of toxicological concern (TTC) limit of 1.5 µg·day−1 under EMA/ICH M7 guidelines; its carry‑through into the subsequent dasatinib N‑alkylation step results in a mutagenic impurity that is difficult to purge and must be controlled to ≤0.10 % by a dedicated HPLC method employing a pentafluorophenyl stationary phase and detection at 210 nm. The second failure mode involves the homodimeric amide arising from trace moisture in the dimethylformamide coupling solvent; this impurity co‑elutes with the product on standard C18 phases unless the acetonitrile fraction is lowered to 35 %. When the area percentage of this dimer exceeds 0.30 %, dasatinib final yield in the subsequent Buchwald–Hartwig amination drops by 12–15 % because the dimer consumes the active palladium catalyst. Users are therefore advised to request a certificate of analysis that reports the individual area percentages of the chloro‑methylaniline starting material and the diamide using the orthogonal chromatographic conditions described, not solely the aggregate purity value.
| Parameter | Specification | Analytical Procedure |
|---|---|---|
| Appearance | Off‑white to pale yellow crystalline powder | Visual, USP 〈167〉 |
| Identification (IR) | Conforms to reference spectrum | FTIR, potassium bromide disk, USP 〈197K〉 |
| Assay (HPLC, anhydrous basis) | 98.0–102.0 % | Reversed‑phase HPLC-UV 254 nm, external standard |
| 2‑Chloro‑6‑methylaniline content | ≤0.10 % | HPLC with pentafluorophenyl phase, 210 nm |
| Individual unspecified impurity | ≤0.15 % | Same as Assay method |
| Water content (Karl Fischer) | ≤0.50 % | Coulometric, EPA 9001 compliant |
| Residual solvents: DMF | ≤880 ppm | Headspace GC‑FID, USP 〈467〉 Class 2 |
| Residual solvents: Acetonitrile | ≤410 ppm | Same method |
| Heavy metals (as lead) | ≤10 ppm | Sulfide precipitation, USP 〈231〉 |
| Loss on drying (105 °C, 3 h) | ≤0.50 % | Gravimetric, USP 〈731〉 |
Storage stability studies conducted according to ICH Q1A(R2) conditions confirm that the compound retains 99.0 % purity for 36 months when held in double polyethylene bags inside a sealed, desiccated aluminium‑laminate pouch at −20 °C ± 5 °C. Exposure to relative humidity above 60 % at 25 °C produces a measurable hydrate form detectable by a new endotherm at 92 °C in DSC after 48 h; this form resists re‑conversion to the anhydrous polymorph upon vacuum drying at 40 °C and must be avoided for solid‑state charged reactions. Consequently, all production‑scale aliquots are packaged with a moisture‑activated silica gel canister and supplied with a lot‑specific moisture specification.
Process‑Scale Handling and Batch‑to‑Batch Consistency from 50‑L Glass‑Lined Reactors
When integrating the intermediate into a current good manufacturing practice (cGMP) synthesis of dasatinib monohydrate, the coupling mode of the thiazole amine with 2‑(chloro)‑N‑(2‑hydroxyethyl)‑N‑methyl‑6‑(pyrimidin‑4‑yl)benzamide is a decisive step. Batch‑to‑batch consistency in the particle size distribution of the intermediary product has been found critical for suspending the solid in acetonitrile prior to Pd2(dba)3‑Xantphos catalysis. Over 15 commercial batches manufactured under an ISO 9001:2015 quality management system, the 90th percentile of particle size (D90) by laser diffraction ranged from 68 µm to 112 µm; batches with D90 exceeding 105 µm required an additional 45–60 min of high‑shear mixing using an IKA T18 digital Ultra‑Turrax at 15,000 rpm to achieve complete dissolution in the reaction medium. This variance is attributed to inter‑batch supersaturation gradients during the rapid anti‑solvent addition step in a 50‑L Scharlau‑type borosilicate reactor equipped with a retreat‑curve impeller. Operators accustomed to intermediates supplied for nilotinib or imatinib precursors, which typically exhibit a broader acceptable particle size window of 40–200 µm, discover that the dasatinib-specific intermediate demands tighter crystallisation control because the subsequent Pd‑catalysed coupling is mass‑transport limited. A specification for D90 ≤110 µm is now routinely enforced when the downstream process runs in a fixed vessel configuration without ultrasonication.
In contrast to 2‑amino‑N‑(4‑(pyridin‑2‑yl)phenyl)thiazole‑5‑carboxamide intermediates employed in the assembly of certain FLT3 inhibitors, the present compound lacks the Lewis‑basic pyridine nitrogen that accelerates oxidative addition with palladium. The absence of that coordinating site reduces the risk of off‑cycle palladium‑black formation yet mandates a higher catalyst loading, typically 2.5 mol % Pd2(dba)3 and 6.0 mol % Xantphos, to achieve 92 % conversion within 4 h at reflux. For route scouting chemists evaluating cost‑of‑goods, this translates to a palladium expenditure that is roughly 18 % higher than that required for the better‑known nilotinib precursor. Published data for fully continuous‑flow amination of this specific chloro‑methylphenyl thiazole carboxamide are limited, but milliscale experiments with a Chemtrix Labtrix S1 microreactor indicate that residence times below 120 s lead to substantial carry‑over of unreacted starting material unless the temperature is pushed to 135 °C, at which point the 2‑amino group begins to undergo self‑condensation with the carboxamide carbonyl, generating a cyclic pyrimido‑thiazine by‑product. This thermal boundary is not encountered with the corresponding 4‑fluoro‑3‑methylphenyl isostere, giving formulation developers a clear branching point in their synthetic strategy. The operational window for the current intermediate is therefore defined by a lower temperature limit set by reaction kinetics and an upper limit at 130 °C governed by the onset of intramolecular degradation, making precise jacket‑temperature control on the pilot scale non‑negotiable.
Supply chain variability is further attenuated by the availability of the compound in research‑grade (97 %) and GMP‑grade (99 + %) streams. The latter is accompanied by a full validation package, including a BSE/TSE statement in accordance with EMA/410/01 Rev. 3, elemental impurity risk assessment per ICH Q3D, and nitrosamine risk evaluation conducted by modulation of nitrite trapping experiments with ascorbic acid. Such documentation is generally absent for lower‑cost generic analogues of the 2‑aminothiazole‑5‑carboxamide core that are marketed solely by purity and colour, and that disparity becomes material during the pre‑approval inspection of the downstream drug substance file under Common Technical Document format.
